Navigation Links
Albuferon in Medical News

HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C

ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced the final results of a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatit...

HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C

ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the final quality-of-life results from a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...Drugs in Select Countries (includes corresponding Graph/Chart) II-3 albuferon - Rising Above the Standards II-4 Viramidine - Next-Generation Ribaviri...s with GI-5005 II-57 Human Genome Gets Encouraging Interim Results with albuferon II-58 Intarcia Releases Study Results of Omega Interferon II-58 Nau...

Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)

... of required injections. As a result, the value of HGSI shares was reduced by 57% the day the study data was released. I can't help but wonder how albuferon might have performed in combination with our Hemopurifier(R)? Regardless, a drug candidate wishing to supplant SOC therapy in the market will need to...

Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors

...ducts may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. SAFE HARBOR STATEMENT This announcement contains forward-looking statements within ...
Albuferon in Medical Technology

Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon

- Albuferon 900-mcg dosed every two weeks achieved an SVR rate at least comparable to Pegasys dosed every week (ITT analysis), with more favorable quality-of-life scores - ROCKVILLE, Md., June 07, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced the top-line final results...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the submission of global marketing applications is expected in fall 2009. BENLYSTA successfully met its pr...

Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)

...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing a... (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. SAFE ...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

...as many injections, in two pivotal Phase 3 trials, albuferon (albinterferon alfa-2b) met the primary efficacy e...eron alfa-2a) - - Patients receiving 900-mcg albuferon had comparable rates of serious and/or severe adve... the half-life of the therapeutic proteins. albuferon is being developed by HGS and Novartis for the tre...

Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C

... - 900-mcg albuferon (albinterferon alfa-2b) dosed every two weeks met ...c hepatitis C - - Patients receiving 900-mcg albuferon had comparable rates of serious and/or severe adve...Pegasys) in ACHIEVE 1, a Phase 3 clinical trial of albuferon in combination with ribavirin in treatment-naive p...

Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments

...e reported our company's first Phase 3 results for albuferon in chronic hepatitis C, and the data were positive. We will have results of the second albuferon Phase 3 trial in March 2009, and the results of ou...or 2008 included $35.4 million recognized from the albuferon agreement with Novartis, and $6.5 million in reven...

Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile

...an Electronic Press Kit on this announcement, please click here: http://www.firstlinemedia.com/epk/hgs/ . HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking st...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... that the results of ACHIEVE 2/3 demonstrated that albuferon (albinterferon alfa-2b) met its primary endpoint o...ic response was comparable for the 900-mcg dose of albuferon administered every two weeks, vs. the standard 180...e. The results of ACHIEVE 1, the Phase 3 trial of albuferon in genotype 1 chronic hepatitis C, are expected in...

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

...ted from spam bots, you need JavaScript enabled to view it or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking statements within ...

Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial

...ducts may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. Safe Harbor Statement This announcement contains forward-looking statements within ...
Albuferon in Biological Technology

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has successfully completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. BENLYSTA has successfully m...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are o...

Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)

...cted by Novartis evaluating safety and efficacy of albuferon administered every four weeks in combination with ...ients with genotypes 2 and 3 chronic hepatitis C. albuferon is being developed by HGS and Novartis under an ex...on a weekly basis. A monthly dosing schedule with albuferon may well result in more patients choosing to be tr...

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

...lization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 trials of BENLYSTA are o...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... - Positive results for second Phase 3 trial of albuferon (R) in chronic hepatitis C; global marketing ap...ved our first product sales with ABthrax, and both albuferon and LymphoStat-B(R) continued to make excellent pr...e results from the second of two pivotal trials of albuferon in chronic hepatitis C, and we plan global marketi...

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon has now completed Phase 3 development, and the filing of global marketing a... (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc. HGS ...

Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes

...erferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. albuferon successfully met its primary endpoint in the first of two Phase 3 trials in chronic hepatitis C; results of the second albuferon Phase 3 trial are expected in March 2009. Two Phase 3 clinical trials of L...

Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C

...ted by Novartis to evaluate safety and efficacy of albuferon administered every four weeks in combination with ...ients with genotypes 2 and 3 chronic hepatitis C. albuferon is being developed by HGS and Novartis under an ex...ctions." In December 2008, HGS announced that albuferon met its primary endpoint of non-inferiority to peg...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

... - albuferon (albinterferon alfa-2b) met its primary endpoint o...patitis C - - Patients receiving 900-mcg albuferon had comparable rates of serious adverse events, se...gasys) in ACHIEVE 2/3, a Phase 3 clinical trial of albuferon in combination with ribavirin in treatment-naive p...

Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments

... are on track to report our first Phase 3 data for albuferon in December 2008. We are on track to report our fi...emains on track to have the first Phase 3 data for albuferon - from the ACHIEVE 2/3 trial - in December 2008. A...nsion 3550. HGS, Human Genome Sciences, ABthrax, albuferon and LymphoStat-B are trademarks of Human Genome Sc...
Other Tags
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Men who ... aggressive prostate cancer, a new study suggests. But ... several urologists not involved with the study said more ... are truly accurate. For the study, Harvard researchers ... were followed for 24 years, starting in 1986. During ...
(Date:7/10/2014)... Service (EMS) responders felt better prepared to respond to ... according to a new study in the journal ... study to specifically examine the EMS provider comfort level ... has not yet been neutralized or working with law ... the Columbine High School shooting, the Virginia Tech campus ...
(Date:7/10/2014)... top public health concerns in the United States, with ... as of 2012. As health problems such as childhood ... to discuss the problem. , A new study, led ... Brown School at Washington University in St. Louis, examined ... track Twitter conversations about the issue of overweight kids. ...
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) ... quality of life. Some patients have disturbed sleep/wake ... asleep, while other patients may be subject to ... extreme, PD patients may exhibit REM-sleep behavior disorder ... re-enactment, even before motor symptoms appear. A review ...
(Date:7/10/2014)... the clinical indicators most strongly associated with concussion is ... evidence-based guidelines for concussion diagnosis, prognosis, and treatment, according ... , official journal of the Congress ... Lippincott Williams & Wilkins , a part of ... on analysis of the best available research data, a ...
Breaking Medicine News(10 mins):Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3
(Date:7/10/2014)... , June 27, 2014  The American Academy ... Institute of Standards and Technology (NIST) and the ... academic research and forensic science expert members to ... is an element of the NIST,s Organization of ... among the first appointments made to the new ...
(Date:7/10/2014)... N.Y. , July 2, 2014 It ... (ABD) to announce the appointment of the world-renowned Thoracic ... Board of Directors. Dr. Ginsburg, with over ... facilities: NY Presbyterian Hospital and Good Samaritan Regional Medical ... Pacemaker since the late 1980,s and is considered an ...
(Date:7/10/2014)... 7, 2014 According to a ... Access Control Systems Market Global Forecast, Market Share, Size, ... Electronic Access Control systems market was valued at USD ... at a CAGR of 12.6% from 2014 to 2019, ... in 2019. Browse the full Electronic Access ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5
Other Contents